John Furey helped propel Spark to a groundbreaking FDA approval. Can he do the same for another Philly biotech company?
Proscia has developed software and artificial intelligence tools to make pathology more accurate and efficient.
Spark Therapeutics board member Steve Altschuler shares his thoughts on the challenges of big pharma acquisitions.
The two local companies are combining new tech and genetic testing to improve outcomes for patients.
The first-of-its-kind space boasts a 25,000-square-foot training facility that could help close the local bioprocessing workforce gap.
The funding from the U.S. Department of Commerce will bring more than $1 million and 100 jobs to the region.
The company’s personalized genetic testing service could help clinicians more accurately diagnose and treat an array of mental health conditions.
With its free summer programs at the Science Center, FirstHand could lead more youth to careers in science.
The clinical trial could advance treatment for people with mild-to-moderate Alzheimer’s disease.
Opertech Bio is working with pharmaceutical companies to improve the taste of everything from children’s cough syrup to toothpaste.
Its latest annual report shows how much it has invested in female, minority, and immigrant founders.
Chris Molineaux, the president of Pennsylvania’s only life sciences trade association, explains how Philadelphia can attract more investors and talent.
InstaMed, now backed by JP Morgan Chase, could become the standard for medical billing and payments.
Here’s how the pharma giant is working to ensure safer pregnancies and childbirths for moms in Philly
NeuroFlow’s software enables behavioral health specialists and psychologists to remotely monitor a patient’s mental wellness.